Monday, May 04, 2020 4:28:09 PM
4:20 pm ET May 4, 2020 (Benzinga)
Chembio Diagnostics (NASDAQ:CEMI) reported quarterly losses of $(0.290) per share which missed the analyst consensus estimate of $(0.230) by 26.09 percent. This is a 107.14 percent decrease over losses of $(0.140) per share from the same period last year. The company reported quarterly sales of $6.900 million which missed the analyst consensus estimate of $7.730 million by 10.74 percent. This is a 16.88 percent decrease over sales of $8.301 million the same period last year.
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.*Chembio Diagnostics shares are trading lower after the company reported worse-than-expected Q1 EPS and sales results.(Benzinga)
Disappointing!
Rayank
Recent CEMI News
- Life Science Outsourcing, Inc. Welcomes Neil A. Goldman as Chief Financial Officer • PR Newswire (US) • 10/17/2023 09:00:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM